Taken together, our results demonstrate that BRG‐1 promotes the malignant phenotype of GBM cells, by promoting invasion and migration, reguating the STAT3 pathway, and decreasing chemotherapy sensitivity. The gene discussed is STAT3; the disease is glioblastoma.